Abstract:Activated leukocyte cell adhesion molecule (ALCAM, or CD166) is a cell adhesion molecule and one of potential tumour metastasis 'soil' receptors that via homotypic and heterotypic interactions, mediates cancer cell adhesion. The present study investigated clinical, pathological and prognostic values of ALCAM in patients with pancreatic cancer. Human pancreatic cancer (PANC-1 and Mia PaCa-2) and human vascular endothelial cell lines were used to construct cell models differentially expressing levels of ALCAM. Tumour-endothelial interaction and tumour migration were assessed by a DiI-based method and electric cell-substrate impedance sensing (ECIS) assay. Pancreatic cancer tissues (n=223), collected immediately after surgery, were analysed for levels of the ALCAM transcripts, which were also analysed against clinical, pathological and clinical outcomes of the patients. ALCAM protein was assessed by immunohistochemistry on a tissue array. Our study demonstrate that pancreatic cancer tissues had significantly higher levels of ALCAM transcripts than normal tissues (P<0.00001). There were no significant differences with staging, differentiation and tumour locations. Tumours from patients who died of pancreatic cancer had significantly high levels of ALCAM compared with those who lived (P=0.018), and this finding was further supported by ROC analysis (P=0.016). Multivariant analysis showed that ALCAM is an independent prognosis factor for overall survival (HR=5.485), with both nodal status and TNM staging contributing to the model (HR=2.578 and 3.02, respectively). A surprising finding was the relationship between ALCAM expression and microvessel embolism of tumour cells (P=0.021, with vs without tumour embolism). Levels of ALCAM were found to be a determinant factor to adherence of the pancreatic cancer cells to vascular endothelial cells, as demonstrated by pancreatic cancer cell models genetically engineered to express differential levels of ALCAM. The tumour-endothelial interaction mediated by ALCAM was readily blocked by addition of soluble ALCAM. Our data supports the conclusion that ALCAM expression is aberrant in pancreatic cancer and its raised expression is an independent prognostic factor for the survival of the patients and the microvascular embolism by cancer cells. Our results suggest that ALCAM plays a key role in mediating tumour-endothelial cell interactions and enhancing tumour embolism in pancreatic cancer, and targeting ALCAM represents a potential therapeutic strategy for treating human pancreatic cancer.

JAML Overexpression in Tumour Vascular Endothelial Cells Promotes Cancer Proliferation Via Angiogenesis Through VEGF Signalling Pathway Activation

JAML overexpressed in colorectal cancer promotes tumour proliferation by activating the PI3K-AKT-mTOR signalling pathway

Junctional Adhesion Molecule-Like Protein Promotes Tumor Progression and Metastasis via p38 Signaling Pathway in Gastric Cancer

Profiling of Micrornas in Aml Cells Following Overexpression or Silencing of the Vegf Gene

Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment

Junctional Adhesion Molecule-Like Protein (JAML) is Correlated with Prognosis and Immune Infiltrates in Lung Adenocarcinoma

Overexpression Of Jam-A In Non-Small Cell Lung Cancer Correlates With Tumor Progression

JWA Inhibits Melanoma Angiogenesis by Suppressing ILK Signaling and is an Independent Prognostic Biomarker for Melanoma.

Identification and Validation of JAM-A as a Novel Prognostic and Immune Factor in Human Tumors

Dysregulation of JAM-A Plays an Important Role in Human Tumor Progression.

Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Pancreatic Cancer, a Pivotal Link to Clinical Outcome and Vascular Embolism

Junctional adhesion molecule-like protein promotes tumor progression via the Wnt/β-catenin signaling pathway in lung adenocarcinoma

Cross-talk Between Leukemic and Endothelial Cells Promotes Angiogenesis by VEGF Activation of the Notch/Dll4 Pathway.

JAM-A Overexpression is Related to Disease Progression in Diffuse Large B-cell Lymphoma and Downregulated by Lenalidomide

Apj(+) Vessels Drive Tumor Growth and Represent a Tractable Therapeutic Target

JAM2 is a prognostic biomarker and inhibits proliferation, metastasis and epithelial–mesenchymal transition in lung adenocarcinoma

VCAM1 Promotes Tumor Cell Invasion and Metastasis by Inducing EMT and Transendothelial Migration in Colorectal Cancer

Expression of ALCAM in Clinical Colon Cancer and Relationship With Patients’ Treatment Responses

YAP Overexpression in Breast Cancer Cells Promotes Angiogenesis Through Activating YAP Signaling in Vascular Endothelial Cells

Breast Cancer Cells-Derived Von Willebrand Factor Promotes VEGF-A-related Angiogenesis Through PI3K/Akt-miR-205-5p Signaling Pathway